Page last updated: 2024-11-05

uridine triphosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Uridine Triphosphate: Uridine 5'-(tetrahydrogen triphosphate). A uracil nucleotide containing three phosphate groups esterified to the sugar moiety. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6133
CHEMBL ID336296
CHEBI ID15713
SCHEMBL ID76682
MeSH IDM0022361

Synonyms (71)

Synonym
ins-316
[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl (hydroxy-phosphonooxyphosphoryl) hydrogen phosphate
gtpl1734
uridine 5'-triphosphoric acid
CHEBI:15713 ,
h4utp
5'-utp
KBIO1_000269
DIVK1C_000269
[[[5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-oxolan-2-yl]methoxy-hydroxy-phosphoryl]oxy-hydroxy-phosphoryl]oxyphosphonic acid
2,4(1h,3h)-pyrimidinedione, 1-[5-o-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-.beta.-d-ribofuranosyl]-
[[(2r,3s,4r,5r)-5-(2,4-dioxopyrimidin-1-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate
SPECTRUM_001697
SPECTRUM5_001167
BSPBIO_003192
uridine 5'-(tetrahydrogen triphosphate)
uteplex
uridine, mono(tetrahydrogen triphosphate) (ester)
uridine 5'-(tetrahydrogen triphosphate) (8ci,9ci)
63-39-8
uridine triphosphate
UTP ,
uridine 5'-triphosphate
uridine-5'-triphosphate
C00075
DB04005
IDI1_000269
NCGC00163323-01
einecs 200-558-7
brn 0071520
ins316
KBIO2_007313
KBIOSS_002177
KBIO2_004745
KBIO2_002177
KBIOGR_001481
KBIO3_002692
NINDS_000269
SPECTRUM2_000525
SPBIO_000509
SPECTRUM4_000851
SPECTRUM3_001596
DC99D596-4755-4E87-B3AA-F1D6CFEDCE9A
uridine 5''-triphosphoric acid
chembl336296 ,
bdbm50118213
uridine 5''-(tetrahydrogen triphosphate)
5''-utp
BMSE000295
AKOS016011172
4-24-00-01222 (beilstein handbook reference)
ut0s826z60 ,
unii-ut0s826z60
uridine 5'-triphosphate tris salt
uridine triphosphate [who-dd]
uridine 5'-triphosphate [mi]
SCHEMBL76682
PGAVKCOVUIYSFO-XVFCMESISA-N
CS-7777
DTXSID0041147
uridine 5'-triphosphate sodium salt, aldrichcpr
uridintriphosphat
uridine mono(tetrahydrogen triphosphate)
uridine5'-triphosphate
3h-uridine triphosphate
HY-107372
Q32904692
(((2r,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl)triphosphoric acid
((2r,3s,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2h)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl tetrahydrogen triphosphate
utp;uridine 5'-triphosphate
F85566

Research Excerpts

Actions

ExcerptReferenceRelevance
"Uridine triphosphate (UTP) plays a biological role in increasing indirectly the level of intracellular Ca2+."( CaMK II/Ca2+ dependent endoplasmic reticulum stress mediates apoptosis of hepatic stellate cells stimulated by transforming growth factor beta 1.
Dai, L; Feng, F; Liu, H; Wang, L; Xiao, Y, 2021
)
1.34

Toxicity

ExcerptReferenceRelevance
" Neither UTP alone nor in combination with amiloride caused any clinically significant adverse effects on airway mechanics, (subdivisions of) lung volumes, or gas exchange."( Acute safety and effects on mucociliary clearance of aerosolized uridine 5'-triphosphate +/- amiloride in normal human adults.
Bennett, WD; Boucher, RC; Edwards, LJ; Hohneker, KW; Knowles, MR; Olivier, KN; Zeman, KL, 1996
)
0.29
" The secondary outcome measures including the blood uric acid (BUA), 24-h urinary total protein (24-h UTP), blood urea nitrogen (BUN), interleukin (IL)-6, IL-8, tumor necrosis factor-alpha (TNF-α) and adverse effects."( The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness.
Hua, Q; Lin, Y; Liu, X; Luo, Y; Xia, A; Yang, Q; Zheng, K, 2023
)
0.91
"Tongfengding capsules plus conventional treatment is safe and beneficial for adults with gout compared with conventional treatment."( The Chinese patent medicine Tongfengding capsule for gout in adults: a systematic review of safety and effectiveness.
Hua, Q; Lin, Y; Liu, X; Luo, Y; Xia, A; Yang, Q; Zheng, K, 2023
)
0.91

Pharmacokinetics

ExcerptReferenceRelevance
" Pharmacokinetic parameters were estimated using non-compartmental analysis."( Exploring the intracellular pharmacokinetics of the 5-fluorouracil nucleotides during capecitabine treatment.
Beijnen, JH; Derissen, EJ; Huitema, AD; Jacobs, BA; Rosing, H; Schellens, JH, 2016
)
0.43

Compound-Compound Interactions

ExcerptReferenceRelevance
"To observe the effect of Huaiqihuang granules combined with comprehensive nursing intervention on children with primary nephrotic syndrome (PNS) and its effect on renal function index."( Effect of Huaiqihuang Granules Combined with Comprehensive Nursing on Children with Primary Nephrotic Syndrome.
Cui, S; Shan, J; Yang, G; Yang, H, 2022
)
0.72
"Huaiqihuang granules combined with comprehensive nursing treatment in children with PNS can reduce the occurrence of recent recurrence and adverse reactions and improve the cellular immune function and renal function."( Effect of Huaiqihuang Granules Combined with Comprehensive Nursing on Children with Primary Nephrotic Syndrome.
Cui, S; Shan, J; Yang, G; Yang, H, 2022
)
0.72

Bioavailability

ExcerptReferenceRelevance
" Since these phenomena were not associated with enhanced biosynthesis of orotate de novo, the increased glomerular UDP-sugar bioavailability in diabetes is due to enhanced utilization of exogenous orotate."( Glomerular uracil nucleotide synthesis: effects of diabetes and protein intake.
Cortes, P; Dumler, F; Levin, NW; Paielli, DL, 1988
)
0.27
" Studies were designed to assess the bioavailability of 5-phosphoribosyl-1-pyrophosphate (PRPP) in the diabetic renal cortex because PRPP is an important determinant of the de novo synthesis of nucleotides."( Phosphoribosylpyrophosphate bioavailability in diabetic rat renal cortex in vivo.
Cortes, P; Levin, NW; Schoenberger, AM; Venkatachalam, KK; Verghese, CP, 1980
)
0.26
" This study demonstrates that after the induction of diabetes there is a rapid increase in the bioavailability of substrates utilized in the synthesis of glycoproteins and glycosaminoglycans."( Effects of early diabetes on uridine diphosphosugar synthesis in the rat renal cortex.
Cortes, P; Dumler, F; Levin, NW; Sastry, KS; Verghese, CP, 1982
)
0.26

Dosage Studied

ExcerptRelevanceReference
" This dosage schedule resulted in recurrent phosphate trapping predominantly in liver."( Consequences of recurrent phosphate trapping induced by repeated injections of 2-deoxy-D-galactose. Biochemical and morphological studies in rats.
Keppler, DO; Koch, HK; Lattke, H; Lesch, R, 1979
)
0.26
" The dose-response curve for the stimulation by ATP gamma S of phospholipase C was shifted to the right by the presence of UTP, indicating that both compounds act on the same receptors."( Neuronal "nucleotide" receptor linked to phospholipase C and phospholipase D? Stimulation of PC12 cells by ATP analogues and UTP.
Boarder, MR; Murrin, RJ, 1992
)
0.28
" Reviewing the lessions of the PALA-FU experience, this article explains the potential benefits as well as the need for biochemical modulation in cancer chemotherapy, the need for the appropriate dosage ratio between agents in modulation-based clinical trials, and the necessity to determine in patients, by direct biochemical measurements at the tissue level, the dose and temporal relationship between agents that reproduces the pertinent biochemical changes in human tumors that produced the therapeutic success of that particular drug combination in the preclinical model."( Modulation of fluorouracil by N-(phosphonacetyl)-L-asparate: a review.
Kemeny, NE; Martin, DS, 1992
)
0.28
" Reactive Blue 2, a putative P2y-purinoceptor antagonist, caused a rightward shift of both the ATP and UTP dose-response curves."( Comparison of extracellular ATP and UTP signalling in rat renal mesangial cells. No indications for the involvement of separate purino- and pyrimidino-ceptors.
Pfeilschifter, J, 1990
)
0.28
" The tests conducted at different stages of cell culturing established a relationship between the proliferative response of cells, on the one hand, and the dosage and time of injection of nucleotide into cell culture, on the other."( [Proliferative response of HeLa and Hep2 cell lines to exogenous nucleotides].
Khachaturova, TS; Mkrtchian, LN, 1985
)
0.27
" This technique has been used to generate dose-response curves describing the effects of mycophenolic acid and pyrazofurin on individual colonies of Chinese hamster ovary cells."( Ultrasensitive assay for ribonucleoside triphosphates in 50-1000 cells. Application to studies with pyrazofurin and mycophenolic acid.
Henderson, JF; Moyer, JD, 1983
)
0.27
" The sigmoidal shape of the dose-response curve indicated cooperativity in binding of UTP and UDP."( Escherichia coli UMP-kinase, a member of the aspartokinase family, is a hexamer regulated by guanine nucleotides and UTP.
Bârzu, O; Blondin, C; Danchin, A; Gilles, AM; Krin, E; Sakamoto, H; Serina, L; Sismeiro, O, 1995
)
0.29
" Dose-response relationships gave the following order of potency: 2-methylthioadenosine triphosphate (2-MeSATP) > uridine 5'-triphosphate (UTP) > ATP = ADP > inosine 5' triphosphate (ITP)."( Purine- and pyrimidine-stimulated phosphoinositide breakdown and intracellular calcium mobilisation in astrocytes.
Langley, D; Pearce, B, 1994
)
0.29
" Subsequent dosing of ADP (1."( Characterization of ecto-ATPase on human blood cells. A physiological role in platelet aggregation?
Beukers, MW; IJzerman, AP; Kerkhof, CJ; Pirovano, IM; Soudijn, W; van Weert, A, 1993
)
0.29
" In the presence of ATP or UTP, the dose-response curve for ADP action on [Ca2+]i was monophasic and corresponded to the high affinity responses."( ADP induces inositol phosphate-independent intracellular Ca2+ mobilization in brain capillary endothelial cells.
Breittmayer, JP; Frelin, C; Vigne, P, 1993
)
0.29
" Construction of dose-response curves to ATP, ATP gamma S and UTP in the presence and absence of additional agonists showed that responses to ATP gamma S and UTP were not additive, nor were those to UTP and ATP."( Evidence for a nucleotide receptor on adrenal medullary endothelial cells linked to phospholipase C and phospholipase D.
Boarder, MR; Purkiss, JR; Wilkinson, GF, 1993
)
0.29
" Dose-response curves on the production of inositol-1,4,5-trisphosphate and Ca2+ by ATP and UTP were consistently similar."( Expression cloning and signal transduction pathway of P2U receptor in mammary tumor cells.
Enomoto, K; Furuya, K; Maeno, T; Moore, RC; Oka, T; Yamagishi, S,
)
0.13
" To explore the function of NDH II, we studied the intracellular distribution of NDH II of different mammalian species by immunofluorescence and compared these findings with the known role of the Drosophila homologue MLE that is involved in sex-specific gene dosage compensation."( Nucleolar localization of murine nuclear DNA helicase II (RNA helicase A).
Grosse, F; Herrmann, C; Zhang, S, 1999
)
0.3
" Acid blue 129, acid blue 80, and acid violet 34 shifted the dose-response curve of the P2Y1 agonist 2-methylthio adenosine trisphosphate (2MeSATP) to the right."( Evaluation of reactive blue 2 derivatives as selective antagonists for P2Y receptors.
Brown, CA; Brown, J, 2002
)
0.31
" UTP at doses between 500 and 3000 microM resulted in increasing cell death following a normal sigmoid dose-response model."( Cell death induced by uridine 5'-triphosphate (UTP) in contrast to adenosine 5'-triphosphate (ATP) in human epidermoid carcinoma cells (A-431).
Neuhuber, W; Ogilvie, A; Völkl, T, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
pyrimidine ribonucleoside 5'-triphosphate
uridine 5'-phosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (62)

PathwayProteinsCompounds
Pyrimidine Metabolism2353
Amino Sugar Metabolism1731
Galactose Metabolism1234
Nucleotide Sugars Metabolism817
Lactose Synthesis1015
Sialuria or French Type Sialuria1731
Salla Disease/Infantile Sialic Acid Storage Disease1731
Starch and Sucrose Metabolism1626
beta-Ureidopropionase Deficiency2353
UMP Synthase Deficiency (Orotic Aciduria)2353
Dihydropyrimidinase Deficiency2353
MNGIE (Mitochondrial Neurogastrointestinal Encephalopathy)2353
Galactosemia1234
Tay-Sachs Disease1731
Galactosemia II (GALK)817
Galactosemia III817
G(M2)-Gangliosidosis: Variant B, Tay-Sachs Disease1731
Glycogen Synthetase Deficiency1626
Glycogenosis, Type III. Cori Disease, Debrancher Glycogenosis1626
Glycogenosis, Type IV. Amylopectinosis, Anderson Disease1626
Glycogenosis, Type VI. Hers Disease1626
Mucopolysaccharidosis VII. Sly Syndrome1626
Sucrase-Isomaltase Deficiency1626
Congenital Disorder of Glycosylation CDG-IId1015
GLUT-1 Deficiency Syndrome1015
Lamivudine Metabolism Pathway1816
Lipopolysaccharide Biosynthesis4153
Galactose Degradation/Leloir Pathway1318
Amino Sugar and Nucleotide Sugar Metabolism I1733
Amino Sugar and Nucleotide Sugar Metabolism III2340
Peptidoglycan Biosynthesis I3036
Colanic Acid Building Blocks Biosynthesis1723
Lipopolysaccharide Biosynthesis II4053
Lipopolysaccharide Biosynthesis III3352
Peptidoglycan Biosynthesis II3037
1,6-Anhydro-N-acetylmuramic Acid Recycling920
O-Antigen Building Blocks Biosynthesis922
Leloir Pathway612
Amino Sugar and Nucleotide Sugar Metabolism2229
Aminosugars metabolism ( Aminosugars metabolism )1529
UTP + N-Acetyl-D-glucosamine 1-phosphate = Pyrophosphate + UDP-N-acetyl-D-glucosamine ( Aminosugars metabolism )14
Galactose metabolism ( Galactose metabolism )913
UTP + D-Glucose 1-phosphate = Pyrophosphate + UDP-D-glucose ( Glycolysis and Gluconeogenesis )14
Pyrimidine Nucleotides and Nucleosides metabolism ( Pyrimidine Nucleotides and Nucleosides metabolism )4549
UTP + AMP = UDP + ADP ( Pyrimidine Nucleotides and Nucleosides metabolism )14
ATP + UDP = ADP + UTP ( Pyrimidine Nucleotides and Nucleosides metabolism )74
Chitin Biosynthesis921
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
Pyrimidine synthesis and deprivation pathway (COVID-19 Disease Maps)1329
Purinergic signaling053
superpathway of histidine, purine and pyrimidine biosynthesis031
N-acetylglucosamine N-acetylmannosamine and N-acetylneuraminic acid dissimilation012
galactose degradation06
UDP-glucose conversion04
Sucrose biosynthesis06
Glycerol teichoic acid biosynthesis06
De novo biosynthesis of pyrimidine ribonucleotides09
Sucrose metabolism1413
Biochemical pathways: part I0466
Pyrimidine metabolism038
DNA replication02
Glucuronidation014
UDP-L-arabinose biosynthesis (salvage pathway)07

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency2.81840.003245.467312,589.2998AID2517
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency39.81070.004023.8416100.0000AID485290
regulator of G-protein signaling 4Homo sapiens (human)Potency1.68340.531815.435837.6858AID504845
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency28.18381.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2Y purinoceptor 2 Mus musculus (house mouse)IC50 (µMol)1.51001.51001.51001.5100AID436592
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
P2Y purinoceptor 4Rattus norvegicus (Norway rat)EC50 (µMol)2.60002.60002.80003.0000AID150634
Thromboxane A2 receptor Homo sapiens (human)EC50 (µMol)0.10000.02400.98102.4000AID89271
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)EC50 (µMol)0.00700.00070.17911.4500AID305248
P2Y purinoceptor 2 Mus musculus (house mouse)EC50 (µMol)1.26001.26001.26001.2600AID436591
P2Y purinoceptor 2Homo sapiens (human)EC50 (µMol)8.26820.00560.682810.0000AID1372689; AID1372691; AID1372692; AID1372693; AID1372695; AID1465366; AID1465367; AID1465368; AID1465369; AID150321; AID261699; AID272716; AID280297; AID302989; AID304928; AID305248; AID350668; AID350672; AID350677; AID350678; AID350679; AID350683; AID350686; AID350688; AID350690; AID350692; AID350694; AID350696; AID350698; AID373707; AID404832; AID460573; AID484783; AID593124; AID600862; AID600875; AID647894; AID648182; AID682413; AID89269
P2Y purinoceptor 2Rattus norvegicus (Norway rat)EC50 (µMol)0.13000.13000.13000.1300AID261697
P2Y purinoceptor 1Homo sapiens (human)EC50 (µMol)34.66670.00130.42027.2000AID150331; AID304929; AID305249
P2Y purinoceptor 4Homo sapiens (human)EC50 (µMol)0.37580.02301.362310.0000AID150627; AID272719; AID280298; AID304930; AID305250; AID373708; AID404834; AID460576; AID484777; AID593125; AID600863; AID600876; AID647895; AID682414; AID89271
P2Y purinoceptor 6Homo sapiens (human)EC50 (µMol)7.80300.01302.393020.0000AID150636; AID280301; AID304931; AID404830; AID484784; AID593126; AID600864; AID89273
P2Y purinoceptor 11Homo sapiens (human)EC50 (µMol)100.00000.06313.77049.0000AID150489
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RNA-directed RNA polymerase Km10.29500.18002.96006.0000AID261436; AID261437; AID261438; AID278952
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (82)

Processvia Protein(s)Taxonomy
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
smooth muscle contractionThromboxane A2 receptor Homo sapiens (human)
G protein-coupled receptor signaling pathwayThromboxane A2 receptor Homo sapiens (human)
response to nutrientThromboxane A2 receptor Homo sapiens (human)
response to xenobiotic stimulusThromboxane A2 receptor Homo sapiens (human)
positive regulation of blood coagulationThromboxane A2 receptor Homo sapiens (human)
response to testosteroneThromboxane A2 receptor Homo sapiens (human)
thromboxane A2 signaling pathwayThromboxane A2 receptor Homo sapiens (human)
response to ethanolThromboxane A2 receptor Homo sapiens (human)
positive regulation of angiogenesisThromboxane A2 receptor Homo sapiens (human)
positive regulation of smooth muscle contractionThromboxane A2 receptor Homo sapiens (human)
cellular response to lipopolysaccharideThromboxane A2 receptor Homo sapiens (human)
negative regulation of cell migration involved in sprouting angiogenesisThromboxane A2 receptor Homo sapiens (human)
inflammatory responseThromboxane A2 receptor Homo sapiens (human)
positive regulation of blood pressureThromboxane A2 receptor Homo sapiens (human)
positive regulation of vasoconstrictionThromboxane A2 receptor Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationThromboxane A2 receptor Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayThromboxane A2 receptor Homo sapiens (human)
intracellular monoatomic ion homeostasisP2Y purinoceptor 2Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
positive regulation of mucus secretionP2Y purinoceptor 2Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 2Homo sapiens (human)
blood vessel diameter maintenanceP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 2Homo sapiens (human)
positive regulation of protein phosphorylationP2Y purinoceptor 1Homo sapiens (human)
G protein-coupled adenosine receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
monoatomic ion transportP2Y purinoceptor 1Homo sapiens (human)
cell surface receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationP2Y purinoceptor 1Homo sapiens (human)
glial cell migrationP2Y purinoceptor 1Homo sapiens (human)
regulation of cell shapeP2Y purinoceptor 1Homo sapiens (human)
response to mechanical stimulusP2Y purinoceptor 1Homo sapiens (human)
negative regulation of norepinephrine secretionP2Y purinoceptor 1Homo sapiens (human)
signal transduction involved in regulation of gene expressionP2Y purinoceptor 1Homo sapiens (human)
platelet activationP2Y purinoceptor 1Homo sapiens (human)
positive regulation of inositol trisphosphate biosynthetic processP2Y purinoceptor 1Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 1Homo sapiens (human)
eating behaviorP2Y purinoceptor 1Homo sapiens (human)
positive regulation of monoatomic ion transportP2Y purinoceptor 1Homo sapiens (human)
positive regulation of transcription by RNA polymerase IIP2Y purinoceptor 1Homo sapiens (human)
positive regulation of hormone secretionP2Y purinoceptor 1Homo sapiens (human)
establishment of localization in cellP2Y purinoceptor 1Homo sapiens (human)
positive regulation of penile erectionP2Y purinoceptor 1Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeP2Y purinoceptor 1Homo sapiens (human)
response to growth factorP2Y purinoceptor 1Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 1Homo sapiens (human)
cellular response to purine-containing compoundP2Y purinoceptor 1Homo sapiens (human)
protein localization to plasma membraneP2Y purinoceptor 1Homo sapiens (human)
relaxation of muscleP2Y purinoceptor 1Homo sapiens (human)
blood vessel diameter maintenanceP2Y purinoceptor 1Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationP2Y purinoceptor 1Homo sapiens (human)
regulation of synaptic vesicle exocytosisP2Y purinoceptor 1Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
positive regulation of cytosolic calcium ion concentrationP2Y purinoceptor 4Homo sapiens (human)
transepithelial chloride transportP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 4Homo sapiens (human)
cellular response to prostaglandin E stimulusP2Y purinoceptor 4Homo sapiens (human)
regulation of presynaptic cytosolic calcium ion concentrationP2Y purinoceptor 4Homo sapiens (human)
regulation of synaptic vesicle exocytosisP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 4Homo sapiens (human)
phagocytosisP2Y purinoceptor 6Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
activation of phospholipase C activityP2Y purinoceptor 6Homo sapiens (human)
positive regulation of smooth muscle cell migrationP2Y purinoceptor 6Homo sapiens (human)
transepithelial chloride transportP2Y purinoceptor 6Homo sapiens (human)
positive regulation of inositol 1,4,5-trisphosphate-sensitive calcium-release channel activityP2Y purinoceptor 6Homo sapiens (human)
positive regulation of inositol trisphosphate biosynthetic processP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeP2Y purinoceptor 6Homo sapiens (human)
cellular response to prostaglandin E stimulusP2Y purinoceptor 6Homo sapiens (human)
cellular response to purine-containing compoundP2Y purinoceptor 6Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationP2Y purinoceptor 6Homo sapiens (human)
cellular response to pyrimidine ribonucleotideP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 6Homo sapiens (human)
defense responseP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
activation of adenylate cyclase activityP2Y purinoceptor 11Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
calcium-mediated signalingP2Y purinoceptor 11Homo sapiens (human)
neuronal signal transductionP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor signaling pathwayP2Y purinoceptor 11Homo sapiens (human)
cellular response to ATPP2Y purinoceptor 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (20)

Processvia Protein(s)Taxonomy
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
thromboxane A2 receptor activityThromboxane A2 receptor Homo sapiens (human)
guanyl-nucleotide exchange factor activityThromboxane A2 receptor Homo sapiens (human)
protein bindingThromboxane A2 receptor Homo sapiens (human)
protein bindingP2Y purinoceptor 2Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 2Homo sapiens (human)
A1 adenosine receptor bindingP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 2Homo sapiens (human)
G protein-coupled ADP receptor activityP2Y purinoceptor 1Homo sapiens (human)
protein bindingP2Y purinoceptor 1Homo sapiens (human)
ATP bindingP2Y purinoceptor 1Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 1Homo sapiens (human)
ADP bindingP2Y purinoceptor 1Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 1Homo sapiens (human)
G protein-coupled ATP receptor activityP2Y purinoceptor 1Homo sapiens (human)
protein heterodimerization activityP2Y purinoceptor 1Homo sapiens (human)
scaffold protein bindingP2Y purinoceptor 1Homo sapiens (human)
A1 adenosine receptor bindingP2Y purinoceptor 1Homo sapiens (human)
protein bindingP2Y purinoceptor 4Homo sapiens (human)
ATP bindingP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled purinergic nucleotide receptor activityP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 4Homo sapiens (human)
G protein-coupled ADP receptor activityP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled receptor activityP2Y purinoceptor 6Homo sapiens (human)
protein bindingP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled UDP receptor activityP2Y purinoceptor 6Homo sapiens (human)
G protein-coupled UTP receptor activityP2Y purinoceptor 6Homo sapiens (human)
neurotransmitter receptor activityP2Y purinoceptor 11Homo sapiens (human)
signaling receptor activityP2Y purinoceptor 11Homo sapiens (human)
G protein-coupled ATP receptor activityP2Y purinoceptor 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
acrosomal vesicleThromboxane A2 receptor Homo sapiens (human)
plasma membraneThromboxane A2 receptor Homo sapiens (human)
nuclear speckThromboxane A2 receptor Homo sapiens (human)
plasma membraneThromboxane A2 receptor Homo sapiens (human)
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2Y purinoceptor 2Homo sapiens (human)
plasma membraneP2Y purinoceptor 1Homo sapiens (human)
ciliumP2Y purinoceptor 1Homo sapiens (human)
cell surfaceP2Y purinoceptor 1Homo sapiens (human)
postsynaptic densityP2Y purinoceptor 1Homo sapiens (human)
basolateral plasma membraneP2Y purinoceptor 1Homo sapiens (human)
apical plasma membraneP2Y purinoceptor 1Homo sapiens (human)
dendriteP2Y purinoceptor 1Homo sapiens (human)
cell bodyP2Y purinoceptor 1Homo sapiens (human)
postsynaptic membraneP2Y purinoceptor 1Homo sapiens (human)
presynaptic active zone membraneP2Y purinoceptor 1Homo sapiens (human)
glutamatergic synapseP2Y purinoceptor 1Homo sapiens (human)
plasma membraneP2Y purinoceptor 1Homo sapiens (human)
plasma membraneP2Y purinoceptor 4Homo sapiens (human)
basolateral plasma membraneP2Y purinoceptor 4Homo sapiens (human)
apical plasma membraneP2Y purinoceptor 4Homo sapiens (human)
presynaptic active zone membraneP2Y purinoceptor 4Homo sapiens (human)
glutamatergic synapseP2Y purinoceptor 4Homo sapiens (human)
plasma membraneP2Y purinoceptor 4Homo sapiens (human)
plasma membraneP2Y purinoceptor 6Homo sapiens (human)
basolateral plasma membraneP2Y purinoceptor 6Homo sapiens (human)
apical plasma membraneP2Y purinoceptor 6Homo sapiens (human)
plasma membraneP2Y purinoceptor 6Homo sapiens (human)
plasma membraneP2Y purinoceptor 11Homo sapiens (human)
plasma membraneP2Y purinoceptor 11Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (148)

Assay IDTitleYearJournalArticle
AID1465396Selectivity ratio of EC50 for P2Y2 receptor Y114F mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID593125Agonist activity at human recombinant P2Y4 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate intracellular accumulation by scintillation proximity assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors.
AID1465382Selectivity ratio of EC50 for P2Y2 receptor F261A mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID272716Agonist activity at human P2Y2 receptor expressed in 1321N1 cells assessed as IP accumulation by SPA2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
AID350677Agonist activity at N-terminal HA epitope-tagged wild type 1 human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID350708Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor C278S mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID600875Agonist activity at human P2Y22011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor.
AID404834Agonist activity at human P2Y4 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate accumulation by scintillation proximity assay2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists.
AID1465374Agonist activity at P2Y2 receptor R194H mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID647895Agonist activity at human P2Y purinoceptor 4 expressed in human 1321N1 cells assessed as increase in intracellular calcium concentration by spectrofluorimetry2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Boranophosphate isoster controls P2Y-receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues.
AID1372692Agonist activity at P2Y2 receptor in human CF/T43 cells2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
Current knowledge on the nucleotide agonists for the P2Y2 receptor.
AID436591Agonist activity at mouse P2Y2 receptor expressed in NG108-15 hybrid cells assessed as increase in intracellular calcium release by fluorescence assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Synthesis of uracil nucleotide analogs with a modified, acyclic ribose moiety as P2Y(2) receptor antagonists.
AID302989Agonist activity at P2Y2 receptor expressed in 1321N1 cells assessed as cytosolic calcium level2007Journal of medicinal chemistry, Nov-15, Volume: 50, Issue:23
New iantherans from the marine sponge Ianthella quadrangulata: novel agonists of the P2Y(11) receptor.
AID350678Agonist activity at N-terminal HA epitope-tagged wild type 3 human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID89269Agonist activity evaluated as change in the level of cytosolic calcium in 1321N astrocytoma cells infected with a retrovirus encoding the human P2Y2 receptor2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates.
AID600863Agonist activity at human recombinant P2Y4 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate production after 30 mins by scintillation proximity assay2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor.
AID1370003Drug metabolism at 2 mM at pH 1.7 at room temperature after 20 days by 31P NMR method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Highly Selective and Potent Ectonucleotide Pyrophosphatase-1 (NPP1) Inhibitors Based on Uridine 5'-P
AID350692Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R272A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID460573Agonist activity at human P2Y2 receptor expressed in human 1321N1 cells assessed as calcium elevation by fura2/AM assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
5-OMe-UDP is a potent and selective P2Y(6)-receptor agonist.
AID1369982Drug metabolism at 2 mM at acidic pH after 5 days by 31P NMR method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Highly Selective and Potent Ectonucleotide Pyrophosphatase-1 (NPP1) Inhibitors Based on Uridine 5'-P
AID436594Agonist activity at mouse P2Y2 receptor expressed in NG108-15 hybrid cells assessed as increase in intracellular calcium release at 100 uM by fluorescence assay relative to UTP2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Synthesis of uracil nucleotide analogs with a modified, acyclic ribose moiety as P2Y(2) receptor antagonists.
AID304928Agonist activity at human P2Y2 receptor expressed in human 1321N1 by FLIPR assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Novel nucleotide triphosphates as potent P2Y2 agonists.
AID404832Agonist activity at human P2Y2 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate accumulation by scintillation proximity assay2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists.
AID150627The compound was evaluated for antagonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 4 (P2Y4)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID600868Ratio of EC50 for human recombinant P2Y2 receptor expressed in human 1321N1 cells to EC50 for human recombinant P2Y4 receptor expressed in human 1321N1 cells2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor.
AID593126Agonist activity at human recombinant P2Y6 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate intracellular accumulation by scintillation proximity assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors.
AID460812Agonist activity at human P2Y6 receptor expressed in human 1321N1 cells assessed as calcium elevation by fura2/AM assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
5-OMe-UDP is a potent and selective P2Y(6)-receptor agonist.
AID1465369Agonist activity at P2Y2 receptor H184A mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID280297Agonist activity at human recombinant P2Y2 receptor expressed in 1321N1 cells assessed as stimulation of phospholipase C2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate.
AID304929Agonist activity at human cloned P2Y1 receptor expressed in human 1321N1 by FLIPR assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Novel nucleotide triphosphates as potent P2Y2 agonists.
AID350690Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R180A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID1465368Agonist activity at P2Y2 receptor Y288F mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1372695Agonist activity at human P2Y2 receptor expressed in 1321N1 cells assessed as [3H]-inositol phosphate accumulation measured after 90 mins by anion exchange chromatographic method2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
Current knowledge on the nucleotide agonists for the P2Y2 receptor.
AID1465388Selectivity ratio of EC50 for P2Y2 receptor F111A mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID89271Agonist activity evaluated as change in the level of cytosolic calcium in 1321N astrocytoma cells infected with a retrovirus encoding the human P2Y4 receptor2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates.
AID350679Agonist activity at N-terminal HA epitope-tagged wild type 4 human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID600864Agonist activity at human recombinant P2Y6 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate production after 30 mins by scintillation proximity assay2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor.
AID1465367Agonist activity at wild type P2Y2 receptor (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID373707Agonist activity at human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium concentration by dual-excitation spectrofluorimetric analysis2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Identification of hydrolytically stable and selective P2Y(1) receptor agonists.
AID304930Agonist activity at human cloned P2Y4 receptor expressed in human 1321N1 by FLIPR assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Novel nucleotide triphosphates as potent P2Y2 agonists.
AID350683Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y114A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID350686Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R177A_R180A double mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID280298Agonist activity at human recombinant P2Y4 receptor expressed in 1321N1 cells assessed as stimulation of phospholipase C2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate.
AID278952Activity of HCV NS5B RNA polymerase S282T assessed as incorporation of 32P-UMP into RNA2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
AID593124Agonist activity at human recombinant P2Y2 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate intracellular accumulation by scintillation proximity assay2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Structural modifications of UMP, UDP, and UTP leading to subtype-selective agonists for P2Y2, P2Y4, and P2Y6 receptors.
AID1465366Agonist activity at P2Y2 receptor S193A mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID278943Ratio of Kcat to Km for HCV NS5B RNA polymerase S282T mutant2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
AID1370008Drug metabolism at 2 mM at pH 11.7 at room temperature after 20 days by 31P NMR method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Highly Selective and Potent Ectonucleotide Pyrophosphatase-1 (NPP1) Inhibitors Based on Uridine 5'-P
AID305251Agonist activity at human cloned P2Y6 receptor expressed in human 1321N1 by FLIPR assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Novel nucleotide triphosphates as potent P2Y2 agonists with enhanced stability over UTP.
AID1465387Selectivity ratio of EC50 for P2Y2 receptor S193A mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID484776Stability assessed as half life by HPLC in presence of human 1321N1 cell membranes2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.
AID1372693Agonist activity at P2Y2 receptor in BEA cells (unknown origin)2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
Current knowledge on the nucleotide agonists for the P2Y2 receptor.
AID350684Agonist activity at N-terminal HA epitope-tagged wild type 4 human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID261436Activity against HCV 1b BK NS5B deltaC55 RNA polymerase2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis.
AID1465385Selectivity ratio of EC50 for P2Y2 receptor R194H mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1465378Agonist activity at P2Y2 receptor Y269F mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID280301Agonist activity at human recombinant P2Y6 receptor expressed in 1321N1 cells assessed as intracellular calcium mobilization2007Journal of medicinal chemistry, Mar-22, Volume: 50, Issue:6
Molecular modeling of the human P2Y2 receptor and design of a selective agonist, 2'-amino-2'-deoxy-2-thiouridine 5'-triphosphate.
AID272719Agonist activity at human P2Y4 receptor expressed in 1321N1 cells assessed as IP accumulation by SPA2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
AID305250Agonist activity at human cloned P2Y4 receptor expressed in human 1321N1 by FLIPR assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Novel nucleotide triphosphates as potent P2Y2 agonists with enhanced stability over UTP.
AID150321Evaluated for agonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 2 (P2Y2)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID648184Agonist activity at human P2Y4 receptor expressed in human 1321N1 cells assessed as stimulation of PLC-induced [3H]inositol phosphate production at 100 uM after 30 mins by scintillation counting2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Synthesis and P2Y₂ receptor agonist activities of uridine 5'-phosphonate analogues.
AID600862Agonist activity at human recombinant P2Y2 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate production after 30 mins by scintillation proximity assay2011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor.
AID89273Agonist activity evaluated as change in the level of cytosolic calcium in 1321N astrocytoma cells infected with a retrovirus encoding the human P2Y6 receptor2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates.
AID150331Evaluated for agonist activity against phospholipase C coupled P2Y purinoceptor 1 (P2Y1) of human erythrocytes2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID350687Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R177A_R180A double mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID304931Agonist activity at human cloned P2Y6 receptor expressed in human 1321N1 by FLIPR assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Novel nucleotide triphosphates as potent P2Y2 agonists.
AID386066Inhibition of RNA synthesis activity of HSV 1b Con1 NS5B polymerase2007The Journal of biological chemistry, Oct-12, Volume: 282, Issue:41
Characterization of the metabolic activation of hepatitis C virus nucleoside inhibitor beta-D-2'-Deoxy-2'-fluoro-2'-C-methylcytidine (PSI-6130) and identification of a novel active 5'-triphosphate species.
AID350671Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor S296A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID1465389Selectivity ratio of EC50 for P2Y2 receptor Y269F mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID350699Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y198A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID1465411Agonist activity at P2Y2 receptor Y114F mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1465381Selectivity ratio of EC50 for P2Y2 receptor Y114A mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1465386Selectivity ratio of EC50 for P2Y2 receptor Y268F mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1465383Selectivity ratio of EC50 for P2Y2 receptor H184A mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1465380Agonist activity at P2Y2 receptor R292A mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID350668Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor C278S mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID350696Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R194H mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID350693Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R272A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID350674Effect on intracellular calcium level in non transfected human 1321N1 cells2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID310935Inhibition of adenylyl cyclase2007Bioorganic & medicinal chemistry, Apr-15, Volume: 15, Issue:8
A conformational transition in the adenylyl cyclase catalytic site yields different binding modes for ribosyl-modified and unmodified nucleotide inhibitors.
AID350669Ratio of EC50 for N-terminal HA epitope-tagged human P2Y2 receptor Y118A mutant to EC50 for wild type 3 human P2Y2 receptor2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID600876Agonist activity at human P2Y42011Journal of medicinal chemistry, Jun-23, Volume: 54, Issue:12
Pyrimidine nucleotides with 4-alkyloxyimino and terminal tetraphosphate δ-ester modifications as selective agonists of the P2Y(4) receptor.
AID350665Ratio of EC50 for N-terminal HA epitope-tagged human P2Y2 receptor C278S mutant to EC50 for wild type 3 human P2Y2 receptor2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID350697Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R194H mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID1369991Drug metabolism at 2 mM at basic pH after 5 days by 31P NMR method2018Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9
Highly Selective and Potent Ectonucleotide Pyrophosphatase-1 (NPP1) Inhibitors Based on Uridine 5'-P
AID89268Agonist activity evaluated as change in the level of cytosolic calcium in 1321N astrocytoma cells infected with a retrovirus encoding the human P2Y1 receptor at 100 uM; IA is inactive2001Bioorganic & medicinal chemistry letters, Jan-22, Volume: 11, Issue:2
Synthesis and P2Y receptor activity of a series of uridine dinucleoside 5'-polyphosphates.
AID261438Activity against HCV 1b BK NS5B deltaC55-R158K mutant RNA polymerase2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis.
AID1465410Selectivity ratio of EC50 for P2Y2 receptor R272A mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID272722Agonist activity at human P2Y6 receptor expressed in 1321N1 cells assessed as IP accumulation by SPA2006Journal of medicinal chemistry, Nov-30, Volume: 49, Issue:24
Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors.
AID648182Agonist activity at human P2Y2 receptor expressed in human 1321N1 cells assessed as stimulation of PLC-induced [3H]inositol phosphate production after 30 mins by scintillation counting2012Bioorganic & medicinal chemistry, Apr-01, Volume: 20, Issue:7
Synthesis and P2Y₂ receptor agonist activities of uridine 5'-phosphonate analogues.
AID350676Agonist activity at N-terminal HA epitope-tagged wild type human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID261697Activity against rat P2Y2-GFP transfected in HEK293 cells by intracellular calcium increase2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Diadenosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors.
AID682414Agonist activity at human GFP-tagged P2Y4 receptor expressed in human 1321N1 cells assessed as intracellular calcium mobilization by fura2/AM-based fluorescence spectrophotometry2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety.
AID350694Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y118A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID350672Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor S296A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID404830Agonist activity at human P2Y6 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate accumulation by scintillation proximity assay2008Bioorganic & medicinal chemistry, Jun-15, Volume: 16, Issue:12
Synthesis and potency of novel uracil nucleotides and derivatives as P2Y2 and P2Y6 receptor agonists.
AID1372691Agonist activity at P2Y2 receptor in NG108-15 cells (unknown origin)2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
Current knowledge on the nucleotide agonists for the P2Y2 receptor.
AID1465365Selectivity ratio of EC50 for P2Y2 receptor Y288F mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1465379Agonist activity at P2Y2 receptor Y288A mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID305249Agonist activity at human cloned P2Y1 receptor expressed in human 1321N1 by FLIPR assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Novel nucleotide triphosphates as potent P2Y2 agonists with enhanced stability over UTP.
AID647894Agonist activity at human P2Y purinoceptor 2 expressed in human 1321N1 cells assessed as increase in intracellular calcium concentration by spectrofluorimetry2012Journal of medicinal chemistry, Jan-12, Volume: 55, Issue:1
Boranophosphate isoster controls P2Y-receptor subtype selectivity and metabolic stability of dinucleoside polyphosphate analogues.
AID484777Agonist activity at human recombinant P2Y4 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate production by scintillation proximity assay2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.
AID373708Agonist activity at human P2Y4 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium concentration by dual-excitation spectrofluorimetric analysis2009European journal of medicinal chemistry, Apr, Volume: 44, Issue:4
Identification of hydrolytically stable and selective P2Y(1) receptor agonists.
AID350689Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R177A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID1465376Agonist activity at P2Y2 receptor R265A mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID278951Activity of HCV NS5B RNA polymerase assessed as incorporation of 32P-UMP into RNA2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
AID1372689Agonist activity at P2Y2 receptor (unknown origin) assessed as reduction in inositol phosphate accumulation2018Bioorganic & medicinal chemistry, 01-15, Volume: 26, Issue:2
Current knowledge on the nucleotide agonists for the P2Y2 receptor.
AID350688Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R177A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID682413Agonist activity at human GFP-tagged P2Y2 receptor expressed in human 1321N1 cells assessed as intracellular calcium mobilization by fura2/AM-based fluorescence spectrophotometry2012Bioorganic & medicinal chemistry, Sep-15, Volume: 20, Issue:18
UDP made a highly promising stable, potent, and selective P2Y6-receptor agonist upon introduction of a boranophosphate moiety.
AID352541Agonist activity at human P2Y6 receptor expressed in human 1321N1 cells coexpressing phospholipase C-activating G protein assessed as inositol phosphate production at 10 uM by scintillation proximity assay2009Bioorganic & medicinal chemistry letters, Jun-01, Volume: 19, Issue:11
Synthesis and P2Y receptor activity of nucleoside 5'-phosphonate derivatives.
AID350691Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor R180A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID261699Activity against human P2Y2-GFP expressed in A549 cells by intracellular calcium increase2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Diadenosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors.
AID261696Activity against rat P2Y1-GFP transfected in HEK293 cells by intracellular calcium increase2006Journal of medicinal chemistry, Mar-23, Volume: 49, Issue:6
Diadenosine and diuridine poly(borano)phosphate analogues: synthesis, chemical and enzymatic stability, and activity at P2Y1 and P2Y2 receptors.
AID484784Agonist activity at human recombinant P2Y6 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate production by scintillation proximity assay2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.
AID350698Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y198A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID484783Agonist activity at human recombinant P2Y2 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate production by scintillation proximity assay2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.
AID1465372Agonist activity at P2Y2 receptor Y114A mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID484775Stability assessed as half life in aqueous acidic solution at pH 1.2 by HPLC2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.
AID1465370Agonist activity at P2Y2 receptor R110A mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1465375Agonist activity at P2Y2 receptor F261A mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID278942Ratio of Kcat to Km for HCV NS5B RNA polymerase2007Antimicrobial agents and chemotherapy, Feb, Volume: 51, Issue:2
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase.
AID150489Agonist activity against phospholipase C coupled human P2Y purinoceptor 11 (P2Y11)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID484781Agonist activity at human recombinant P2Y6 receptor expressed in human 1321N1 cells assessed as [3H]inositol phosphate production up to 10 uM by scintillation proximity assay2010Journal of medicinal chemistry, Jun-10, Volume: 53, Issue:11
Pyrimidine ribonucleotides with enhanced selectivity as P2Y(6) receptor agonists: novel 4-alkyloxyimino, (S)-methanocarba, and 5'-triphosphate gamma-ester modifications.
AID1465377Agonist activity at P2Y2 receptor Y268F mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1614295Substrate activity at human POLRMT assessed as 5-radiolabled RNA/DNA incorporation levels at 100 uM after 2 hrs by PAGE analysis2019Journal of medicinal chemistry, 02-28, Volume: 62, Issue:4
Discovery of a Series of 2'-α-Fluoro,2'-β-bromo-ribonucleosides and Their Phosphoramidate Prodrugs as Potent Pan-Genotypic Inhibitors of Hepatitis C Virus.
AID350685Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y114A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID261437Activity against HCV 1b BK NS5B deltaC55-R158M mutant RNA polymerase2006Journal of medicinal chemistry, Mar-09, Volume: 49, Issue:5
2-(2-Thienyl)-5,6-dihydroxy-4-carboxypyrimidines as inhibitors of the hepatitis C virus NS5B polymerase: discovery, SAR, modeling, and mutagenesis.
AID1465373Agonist activity at P2Y2 receptor R194A mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID305248Agonist activity at human P2Y2 receptor expressed in human 1321N1 by FLIPR assay2007Bioorganic & medicinal chemistry letters, Jan-15, Volume: 17, Issue:2
Novel nucleotide triphosphates as potent P2Y2 agonists with enhanced stability over UTP.
AID150636The compound was evaluated for agonist activity against phospholipase C coupled recombinant human P2Y purinoceptor 6 (P2Y6)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID150634The compound was evaluated for antagonist activity against phospholipase C coupled recombinant rat P2Y purinoceptor 4 (P2Y4)2002Journal of medicinal chemistry, Sep-12, Volume: 45, Issue:19
Purine and pyrimidine (P2) receptors as drug targets.
AID221765Kinetic constant for galactosyltransferase inhibition was determined1987Journal of medicinal chemistry, Aug, Volume: 30, Issue:8
Synthesis of glycopyranosylphosphonate analogues of certain natural nucleoside diphosphate sugars as potential inhibitors of glycosyltransferases.
AID436592Antagonist activity at mouse P2Y2 receptor expressed in NG108-15 hybrid cells assessed as inhibition of 1 uM UTP-induced intracellular calcium release preincubated 30 mins before UTP challenge by fluorescence assay2009Bioorganic & medicinal chemistry, Jul-15, Volume: 17, Issue:14
Synthesis of uracil nucleotide analogs with a modified, acyclic ribose moiety as P2Y(2) receptor antagonists.
AID350673Agonist activity at N-terminal HA epitope-tagged wild type 3 human P2Y2 receptor expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID1465384Selectivity ratio of EC50 for P2Y2 receptor R194A mutant (unknown origin) to EC50 for wild type P2Y2 receptor (unknown origin)2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1465371Agonist activity at P2Y2 receptor F111A mutant (unknown origin) expressed in human 1321N1 astrocytoma cells assessed as increase in intracellular calcium mobilization after 1 hr by Fluo-4 AM dye based fluorescence assay2017Journal of medicinal chemistry, 10-26, Volume: 60, Issue:20
Molecular Recognition of Agonists and Antagonists by the Nucleotide-Activated G Protein-Coupled P2Y
AID1137665Displacement of [3H]PSB-12150 from human GPR17 expressed in CHO-K1 cell membranes up to 1 mM after 60 mins by liquid scintillation counting2014ACS medicinal chemistry letters, Apr-10, Volume: 5, Issue:4
Development of [(3)H]2-Carboxy-4,6-dichloro-1H-indole-3-propionic Acid ([(3)H]PSB-12150): A Useful Tool for Studying GPR17.
AID460576Agonist activity at human P2Y4 receptor expressed in human 1321N1 cells assessed as calcium elevation by fura2/AM assay2010Journal of medicinal chemistry, Feb-25, Volume: 53, Issue:4
5-OMe-UDP is a potent and selective P2Y(6)-receptor agonist.
AID350918Agonist activity at N-terminal HA epitope-tagged human P2Y2 receptor Y118A mutant expressed in human 1321N1 cells assessed as increase in intracellular calcium level relative to carbachol2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Key determinants of nucleotide-activated G protein-coupled P2Y(2) receptor function revealed by chemical and pharmacological experiments, mutagenesis and homology modeling.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347028Human P2Y2 receptor (P2Y receptors)1995British journal of pharmacology, Sep, Volume: 116, Issue:1
Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate.
AID1346335Human P2Y11 receptor (P2Y receptors)2003Molecular pharmacology, Jun, Volume: 63, Issue:6
Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling.
AID1347028Human P2Y2 receptor (P2Y receptors)2002Journal of medicinal chemistry, Jan-03, Volume: 45, Issue:1
Methanocarba modification of uracil and adenine nucleotides: high potency of Northern ring conformation at P2Y1, P2Y2, P2Y4, and P2Y11 but not P2Y6 receptors.
AID1346426Human P2Y6 receptor (P2Y receptors)1996Biochemical and biophysical research communications, May-15, Volume: 222, Issue:2
Cloning, functional expression and tissue distribution of the human P2Y6 receptor.
AID1346348Human P2Y4 receptor (P2Y receptors)2000Molecular pharmacology, May, Volume: 57, Issue:5
ATP, an agonist at the rat P2Y(4) receptor, is an antagonist at the human P2Y(4) receptor.
AID1346293Rat P2Y4 receptor (P2Y receptors)1998British journal of pharmacology, Jun, Volume: 124, Issue:3
Molecular cloning and characterization of rat P2Y4 nucleotide receptor.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,362)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990421 (17.82)18.7374
1990's806 (34.12)18.2507
2000's761 (32.22)29.6817
2010's308 (13.04)24.3611
2020's66 (2.79)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 44.10

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index44.10 (24.57)
Research Supply Index7.80 (2.92)
Research Growth Index4.57 (4.65)
Search Engine Demand Index72.30 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (44.10)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials20 (0.83%)5.53%
Reviews66 (2.72%)6.00%
Case Studies1 (0.04%)4.05%
Observational0 (0.00%)0.25%
Other2,336 (96.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]